Diagnosis and Trial Options in Sarcoma | Supplements and Featured Publications

September 08, 2022

Javier Martin-Broto, MD, PhD, discusses future research directions of soft tissue sarcoma.

September 07, 2022

August 31, 2022

Jean-Yves Blay, MD, discusses treatment considerations in patients with soft tissue sarcomas.

August 31, 2022

Patricia LoRusso, DO, discusses the benefit of genetic sequencing in soft tissue sarcomas.

August 31, 2022

Javier Martin-Broto, MD, PhD, discusses the current treatment landscape in the first-line setting for soft tissue sarcomas.

June 15, 2022

Javier Martin-Broto, MD, PhD, discusses the role of MDM2 amplification and p53 inactivation in patients with soft tissue sarcoma.

June 15, 2022

Javier Martin-Broto, MD, PhD, discusses the ongoing research of MDM2 agonists in patients with soft tissue sarcoma.

May 24, 2022

Amplification of murine double minute 2 represents a promising target to access the so-called cellular gatekeeper p53 protein in human cancers.

May 19, 2022

Patricia LoRusso, DO, discusses the importance clinical trial enrollment for patients with MDM2-amplified dedifferentiated liposarcoma.

May 19, 2022

Jean-Yves Blay, MD, discusses current treatment challenges in soft tissue sarcomas.

May 12, 2022

Patricia LoRusso, DO, discusses the efficacy observed of BI 907828 in solid tumors in a phase 1 trial.

April 25, 2022

Jean-Yves Blay, MD, discusses the exploration of BI 907828 in patients with sarcoma.